Advances in psychiatry and nuerology


ISSN 1234-8279

ISSN on-line 2449-9315 

 

As of July 2026, the journal's publisher is Wroclaw Medical University: https://ppn.umw.edu.pl/en/about/.

 

CiteScore 2025: 0.4

MNiSW: 20

Index Copernicus 2023: 90.54

Editorial panel
Submitting and reviewing works online
  • Home page
  • >
  • Archive
  • >
  • issue 2
  • >
  • Rebound effect after S1P receptor modulator treatment in a patient with relapsing-remitting multiple sclerosis

Archive 1995–2023

2018, volume 34, issue 2
Case report

Rebound effect after S1P receptor modulator treatment in a patient with relapsing-remitting multiple sclerosis

Maciej Świat1,2, Magdalena Targosz-Gajniak1, Małgorzata Szymańska3, Olga Rezner1
1. Department of Neurology, Regional Hospital Rybnik, Poland
2. Jan Dlugosz University in Czestochowa, Poland
3. Centrum Terapii SM i Chorób Zwyrodnieniowych
Farmakoterapia w Psychiatrii i Neurologii 2018, 34 (2), 139–142
Date of publication: 2018-09-10
Doi: http://dx.medra.org/10.17393/fpn.2018.07.002
Keywords: multiple sclerosis, sphingosine-phosphate receptor modulator, amiselimod
Summary

We present a case report of severe steroid-refractory rebound disease activity after cessation of MT-1303 (amiselimod) treatment in a patient with relapsing-remitting multiple sclerosis (RRMS), which has not been described in the literature previously. MT-1303 is a novel selective sphingosine-phosphate receptor (S1P1) modulator that was discovered by the chemical modification of fingolimod with the aim of avoiding its heart rate-reducing effect.

Article in PDF format
Correspondence address
Małgorzata Szymańska
Centrum Terapii SM i Chorób Zwyrodnieniowych
ul. Załęska 9, 40-571 Katowice, Poland
email: mklecha@wp.pl
You have added an item to your cart
Go to shopping cart
Restore password
Shopping cart (0)
No products in your cart
Subtotal
0,00 zł
Go to checkout
Go to shopping cart
Font size
Contrast
Underlined links